Effect of Gender and Age on the Pharmacokinetics of Repinotan

@article{Heinig2005EffectOG,
  title={Effect of Gender and Age on the Pharmacokinetics of Repinotan},
  author={Roland Heinig and Pavur R. Sundaresan and Anita Shah and Michael Boettcher},
  journal={Clinical Drug Investigation},
  year={2005},
  volume={25},
  pages={125-134}
}
AbstractObjective: Repinotan hydrochloride (repinotan) is a selective, high-affinity, full serotonin receptor agonist at the 5-HT1a subtype that is undergoing clinical development in acute stroke. To investigate whether gender is an important covariable for repinotan pharmacokinetics, two studies were performed in subjects of different age and gender who had been phenotyped as extensive metabolisers for cytochrome P450 (CYP)2D6 using dextromethorphan as model substrate. Subjects and methods… 
Pharmacokinetics of dihydroartemisinin in Artekin tablets for single and repeated dosing in Chinese healthy volunteers
TLDR
The study showed that DHA in Artekin was rapidly absorbed, distributed and eliminated in the healthy subjects and was not affected by gender in a single dose.
A Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetic/Pharmacodynamic Effects of a Targeted Exposure of Intravenous Repinotan in Patients With Acute Ischemic Stroke: Modified Randomized Exposure Controlled Trial (mRECT)
TLDR
The mRECT demonstrated the feasibility of conducting a rigorous trial using a short therapeutic window demanding clinical and radiographic criteria to optimize patient selection and a Point-of-Care test to achieve a targeted exposure to repinotan.
A Randomized , Double-Blind , Placebo-Controlled Trial to Evaluate the Efficacy , Safety , Tolerability , and Pharmacokinetic / Pharmacodynamic Effects of a Targeted Exposure of Intravenous Repinotan in Patients With Acute Ischemic Stroke Modified
TLDR
The Modified Randomized Exposure Controlled Trial (mRECT) demonstrated the feasibility of conducting a rigorous trial using a short therapeutic window demanding clinical and radiographic criteria to optimize patient selection and a Point-of-Care test to achieve a targeted exposure to repinotan.
"A randomized, double-blind, placebo-controlled trial to evaluate the efficacy, safety, tolerability, and pharmacokinetic/ pharmacodynamic effects of a targeted exposure of intravenous repinotan in patients with acute ischemic stroke"
mRECT demonstrated the feasibility of conducting a rigorous trial using a short therapeutic window demanding clinical and radiographic criteria to optimize patient selection and a Point-of-Care test
Evaluation of Optical Coherence Tomography for the Measurement of the Effects of Activators and Anticoagulants on the Blood Coagulation In Vitro
Optical properties of human blood during coagulation was studied using optical coherence tomography (OCT) and the parameter of clotting time derived from the 1/e light penetration depth (d1/e) vs.

References

SHOWING 1-8 OF 8 REFERENCES
Repinotan (BAY × 3702): A 5HT1A Agonist in Traumatically Brain Injured Patients
TLDR
Repinotan treatment had no apparent adverse effects on intracranial pressure, hemodynamic parameters or laboratory parameters and serious adverse events were considered related to drug treatment, with the possible exception of one case of inappropriate ADH secretion.
Psychotropic medications and cytochrome P450 2D6: pharmacokinetic considerations in the elderly.
  • R. Shulman, V. Ozdemir
  • Medicine, Biology
    Canadian journal of psychiatry. Revue canadienne de psychiatrie
  • 1997
TLDR
Clinical measurement of CYP2D6 activity may potentially assist in prediction of doses required to achieve therapeutic plasma concentrations of psychotropics metabolized by CYP 2D6 in individual patients.
Debrisoquine hydroxylation phenotyping in geriatric psychopharmacology.
TLDR
It is found that DBQ oxidative metabolism does not necessarily change with aging, alone, and that (genetic) slow DBQ metabolizers endure into old age, remaining at risk for treatment with many commonly used psychotropics, suggests the need to study the relevance of metabolic phenotyping in elderly psychiatric patients.
Assessment of CYP2D6 activity in very elderly healthy subjects
TLDR
The purpose of the present study was to measure CYP2D6 activity in a very elderly population by use of the dextromethorphan metabolic ratio and to compare it to results obtained in young healthy subjects, which were compared by using the Wilcoxon test for unpaired data.
CYP2D6 and CYP2C19 genotypes in an elderly Swedish population
TLDR
It is indicated that the CYP2D6 and CYP 2C19 genotypes play no major role in the probability of reaching high age, and no genetically determined differences in the pharmacokinetics of drugs metabolized by these two polymorphic enzymes are to be expected in the oldest age groups compared with younger adults.
Polymorphic Drug Oxidation
TLDR
The high incidence of PM (and of heterozygous extensive metabolisers) of S-mephenytoin in Asia might be the reason for the reported higher sensitivity of Orientals to diazepam compared with Caucasians.
How Important Are Gender Differences in Pharmacokinetics?
TLDR
Gender-related differences in pharmacokinetics have frequently been considered as potentially important determinants for the clinical effectiveness of drug therapy and intensive future research efforts are needed to assess the full scope and impact of pharmacodynamic gender disparity on applied pharmacotherapy.